Check out our full report below:
Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome
Read More: Health Canada Date: Apr 23, 2024
US FDA Granted Fast Track Designation to Medicure’s MC-1 for PNPO deficiency
Read More: US FDA Date: Apr 24, 2024
EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment
Read More: EMA Date: Apr 24, 2024
CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy
Read More: CSL Date: Apr 24, 2024
Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain
Read More: Ascendis Date: Apr 25, 2024
Blue Arbor’s RESTORE Neuromuscular Interface System Receives FDA Breakthrough Device Designation & TAP Enrolment
Read More: Blue Arbor Date: Apr 25, 2024
Medivir’s MIV-711 Receives FDA ODD and RPDD for Legg-Calvé-Perthes Disease
Read More: Medivir Date: Apr 25, 2024
US FDA Grants Fast Track Designation to Compass Therapeutics’ CTX-009 with Paclitaxel for Previously Treated Metastatic or Locally Advanced Biliary Tract Tumors.
Read More: US FDA Date : Apr 26,2024
Aurigene and Vipergen Enter into a Strategic Collaboration to Offer DEL Screening and Integrated Drug Discovery Services
Read More: Aurigene and Vipergen Date: Apr22, 2024
Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Diseases
Read More: Ipsen Date: Apr22,2024
Ochre Bio and Boehringer Ingelheim Enter into a Collaboration to Develop and Commercialize Novel Regenerative Treatments for Advanced Liver Disease
Read More: Ochre Bio and Boehringer Date: Apr23,2024
Vertex and Treefrog Therapeutics Sign a Licensing Agreement & Collaborate to Enhance Production of Vertex’s Cell Therapies for Type-I Diabetes
Read More: Vertex and Treefrog Date: Apr 23, 2024
Angle Enters into a Supply Agreement with AstraZeneca to use DDR Assay in Pharmaceutical R&D
Read More: Angle Date: Apr 24, 2024
MFDS Korea Approves Onconic Therapeutics’ JAQBO (Zastaprazan citrate) for Treatment of Gastroesophageal Reflux Disease (GERD) in adults
Read More: MFDS Korea Date: Apr 26, 2024
Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases
Read More: Regeneron Date : Apr 26, 2024
Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets
Read More: Incyte Date: Apr 24, 2024
Labcorp to Acquire Invitae Under US Bankruptcy Code Section 363
Read More: Labcorp Date: Apr 25, 2024
Cochlear’s Osia System Gets FDA Clearance for Children Aged 5 Years and Above
Read More: Cochlear’s Date: Apr 22, 2024
Immunovia Reports Positive Results of Next Generation Test from Model Development Study for Pancreatic Cancer Detection.
Read More: Immunovia Date: Apr 22, 2024
Hepion Pharmaceuticals Begins Wind-Down Activities in ASCEND-NASH P-IIb Study
Read More: Hepion Date: Apr22, 2024
GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease
Read More: GENETIKA+ Date: Apr 23, 2024
Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors of the Lung
Read More: Krystal Biotech Date: Apr 23, 2024
Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)
Read More: Sanofi Date: Apr 23, 2024
Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD
Read More: Neurocrine Date: Apr 24, 2024
CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)
Read More: CureVac Date: Apr 25, 2024
Atom Bioscience Initiates Enrolment in Global P-IIb/III Study of ABP-671 to Treat Chronic Gout in US
Read More: Atom Bioscience Date: Apr 25, 2024
Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024
Read More: Sanofi Date: Apr 17, 2024
GSK to Feature Results from the P-III (ZOSTER-049) Study of Shingrix for Protection Against Shingles at ESCMID Global 2024
Read More: GSK Date: Apr 17, 2024
Roche to Highlight the P-III (OCARINA II) Trial Results of Ocrevus for Treating Progressive and Relapsing Multiple Sclerosis at AAN 2024
Read More: Roche Date: Apr 17, 2024
GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024
Read More: GSK Date: Apr 18, 2024
Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
Read More: Eli Lilly Date: Apr 18, 2024
Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis
Read More: Artiva Date: Apr 18, 2024
Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Disease
Read More: Cerevel Date: Apr 19, 2024
Oncternal Therapeutics Reports First Patient Dosing in Fourth Cohort of P-I/II Study of ONCT-534 for the Treatment of R/R mCRPC
Read more: Oncternal Therapeutics Date: Apr19,2024
Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers
Read more: Ventus Therapeutics Date: Apr19,2024
Cresilon Teams Up with Covetrus, MWI Animal Health, and Patterson Veterinary Supply for VETIGEL (Haemostatic Gel)
Read More: Cresilon Date: Apr 22, 2024
